PF-06946860

BIOLOGICAL4 trials

Sponsors

Pfizer

Conditions

AnorexiaBreast CancerCachexiaColorectal CancerFatigueHealthyLoss of AppetiteNon-Small-Cell Lung Cancer

Phase 1

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

CompletedNCT03599063

Start: 2018-07-30End: 2019-09-18Updated: 2019-11-08

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

CompletedNCT03974776

Start: 2019-07-08End: 2020-01-10Updated: 2020-01-29

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

CompletedNCT04299048

PfizerCachexia, Colorectal Cancer, Non-Small-Cell Lung Cancer +1

Start: 2020-11-17End: 2022-03-30Updated: 2023-12-14

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

CompletedNCT04803305

PfizerAnorexia, Breast Cancer, Cachexia +7

Start: 2021-05-11End: 2022-08-09Updated: 2024-01-12

Related Papers

Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design

Journal of Cachexia Sarcopenia and Muscle2024-03-1833 citations

Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy

Cancer Research2023-04-145 citations